Belantamab mafodotin (Blenrep®) Horizons Infosheet

This Horizon Infosheet provides information about belantamab mafodotin (Blenrep®), a drug being investigated for the treatment of myeloma.

This Horizon Infosheet covers key questions about belantamab mafodotin (Blenrep®), such as:

  • What is belantamab mafodotin (Blenrep®)?
  • How does belantamab mafodotin work?
  • How is belantamab mafodotin given?
  • What evidence exists to support the use of belantamab mafodotin?
  • What are the possible side effects of belantamab mafodotin?
  • Is belantamab mafodotin currently available in any UK trials?
  • What is the availability of belantamab mafodotin in the UK?
  • What are the future directions of research for belantamab mafodotin?

Key points you can read about in this Horizons Infosheet include:

  • Belantamab mafodotin (Blenrep®) is a new drug being investigated for the treatment of myeloma
  • Belantamab mafodotin is a type of drug called an antibody-drug conjugate
  • The drug contains a monoclonal antibody which targets proteins called BCMA on myeloma cells. This is linked to a chemotherapy drug
  • The chemotherapy drug is delivered directly to myeloma cells, and once inside them can kill them
  • Belantamab mafodotin has shown effectiveness in patients with relapsed and/or refractory myeloma who have received several previous lines of treatment, and further clinical trials are underway or planned
  • Side effects seen so far with belantamab mafodotin have included changes to the surface of the eye, blurred vision, lower levels of platelets in the blood, and anaemia
  • Changes to the surface of the eye (sometimes with no symptoms) are common, and patients have regular eye checks during treatment
  • Belantamab mafodotin is not available for use on the NHS. However, patients may be treated with it through a clinical trial

Myeloma UK Belantamab mafodotin Horizons Infosheet

PDF / 258KB Download
Close-up photograph of a hand holding a mobile phone.

Stay in touch

We’d love to stay in touch. Join our mailing list to receive updates from Myeloma UK including our monthly newsletter and updates about our services, research, campaigns and other ways you can get involved.